Original language | English |
---|---|
Pages (from-to) | 1-8 |
Number of pages | 8 |
Journal | Atherosclerosis Supplements |
Volume | 39 |
DOIs | |
Publication status | Published - Dec 2019 |
Externally published | Yes |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Atherosclerosis Supplements, Vol. 39, 12.2019, p. 1-8.
Research output: Contribution to journal › Other Journal Article › peer-review
TY - JOUR
T1 - The role of red yeast rice (RYR) supplementation in plasma cholesterol control
T2 - A review and expert opinion
AU - Banach, Maciej
AU - Bruckert, Eric
AU - Descamps, Olivier S.
AU - Ellegård, Lars
AU - Ezhov, Marat
AU - Föger, Bernhard
AU - Fras, Zlatko
AU - Kovanen, Petri T.
AU - Latkovskis, Gustavs
AU - März, Winfried
AU - Panagiotakos, Demosthenes B.
AU - Paragh, György
AU - Pella, Daniel
AU - Pirillo, Angela
AU - Poli, Andrea
AU - Reiner, Željko
AU - Silbernagel, Günter
AU - Viigimaa, Margus
AU - Vrablík, Michal
AU - Catapano, Alberico L.
N1 - Funding Information: M. Banach has received research grant(s)/support from Sanofi and Valeant, and has served as a consultant for Akcea, Amgen, KRKA, MSD, Mylan, Polfarmex, Polpharma, Sanofi-Aventis, Servier, Esperion, and Resverlogix; E. Bruckert reports grants from Amgen, and personal fees from Aegerion, Genfit, MSD, Sanofi/Regeneron Pharmaceuticals Inc, AstraZeneca, Unilever, Servier and AKCEA; O. Descamps reports that his institution (Centres Hospitaliers Jolimont) received grants for his research and payment for him conducting clinical trials from Amgen, Sanofi, AstraZeneca, MSD. He received personally consulting fees and/or honoraria for delivering lectures for Amgen, Sanofi, AstraZeneca, MSD, Servier, Eurogenerics and Mylan; L. Ellegård L.E. reports no conflicts of interest; M. Ezhov reports lecture fees from Amgen, AstraZeneca, Berlin Chemie, Egis, KRKA, NovoNordisk, Pfizer, Recordati, and Sanofi; and consultant fees from Amgen, NovoNordisk, and Sanofi; B. Föger B. Föger reports personal fees and grants from Amgen, Böhringer Ingelheim, MEDA, MSD, Sanofi, and Sanova; Z. Fras; P. Kovanen reports personal fees as Company consultant and/or speaker for Aegerion, Amgen, Medaffcon, Raisio, Sanofi/Regeneron; G. Latkovskis reports grants, personal fees or non-financial support from Abbott Laboratories, Amgen, Astra-Zeneca, Bayer, Berlin-Chemie/Menarini, Boehringer Ingelheim, GlaxoSmithKline, KRKA, Mylan, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, Sanofi-Aventis, Servier, Siemens Healthcare, Zentiva; W. März reports grants and personal fees from Abbott Diagnostics, Aegerion Pharmaceuticals, Akcea Therapeutics, Alexion Pharmaceuticals, AMGEN, BASF, Berlin-Chemie, Numares AG, Sanofi, and grants from Astrazeneca, Bayer Vital GmbH, bestbion dx GmbH, Boehringer Ingelheim Pharma GmbH Co KG, Immundiagnostik GmbH, Merck Chemicals GmbH, MSD Sharp and Dohme GmbH, Novartis Pharma GmbH, Olink Proteomics, Siemens Healthineers, all outside the submitted work. W.M. is employed with SYNLAB Holding Deutschland GmbH; D.B. Panagiotakos reports no conflicts of interest; G. Paragh reports to be a Member of the Professional Advisory Board: Sanofi – Aventis Zrt., AMGEN, MSD Pharma Hungary Kft; D. Pella reports grants and personal fees from AMGEN, Boehringer Ingelheim, Krka, MSD Sharp and Dohme GmbH, Mylan, Pfizer, Sanofi-Aventis, Servier, Pfizer; A. Pirillo reports no conflict of interest; A. Poli reports to be Chairman of NFI - Nutrition Foundation of Italy, a non-profit organization partially supported by 19 food and beverage companies, some of which market food or food supplements active on plasma cholesterol levels; Ž. Reiner has received honoraria from Sanofi Aventis but there are no disclosures regarding this article; G. Silbernagel reports grants and personal fees from Sanofi, grants and personal fees from Amgen, grants from Numares, and grants and personal fees from Bayer, outside the submitted work; M Viigimaa reports grants from Amgen, and lecture honoraria from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Servier, Sanofi and Menarini; M. Vrablík reports grants, personal fees or non-financial support from Abbott Laboratories, Amgen, Astra-Zeneca, Boehringer Ingelheim, KRKA, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, Servier, Zentiva outside of the submitted work; A.L. Catapano reports grants from Sanofi, Regeneron, Merck, Mediolanum, grants from SigmaTau, Menarini, Kowa, Recordati, Eli Lilly, personal fees from Merck, Sanofi, Regeneron, AstraZeneca, Amgen, Sigma Tau, Recordati, Aegerion, Kowa, Menarini, Eli Lilly, Genzyme, outside the submitted work. Funding Information: This article was sponsored by the Societ? Italiana di Terapia Clinica e Sperimentale - SITeCS. SITeCS wishes to thank Mylan for providing an unrestricted educational grant to support the scientific consensus meeting. The grant was used in part for the publication of the present supplement. Mylan had no interference in the organization and scientific output of the meeting and had no involvement in this publication.
PY - 2019/12
Y1 - 2019/12
UR - http://www.scopus.com/inward/record.url?scp=85071114460&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosissup.2019.08.023
DO - 10.1016/j.atherosclerosissup.2019.08.023
M3 - Other Journal Article
C2 - 31451336
AN - SCOPUS:85071114460
SN - 1567-5688
VL - 39
SP - 1
EP - 8
JO - Atherosclerosis Supplements
JF - Atherosclerosis Supplements
ER -